Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Multi-epitope folate receptor alpha-loaded dendritic cell vaccine
- Development stage
- Phase 2
- Lead developer
- Mayo Clinic
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
A personalized, autologous, cell-based cancer vaccine composed of a patient's own monocyte-derived dendritic cells loaded with five immunogenic peptide epitopes derived from the folate receptor alpha (FRα) protein. The purpose of this therapy is to stimulate the immune system—specifically T-cell and antibody responses—against tumor cells that overexpress FRα. This approach has been studied primarily in ovarian cancer patients and has demonstrated safety as well as induction of antigen-specific Th1, Th17, and antibody responses associated with prolonged recurrence-free survival. The primary developer is Mayo Clinic[1][2][3][8].
- Other names
- FRα-loaded dendritic cell vaccinefolate receptor alpha-loaded dendritic cell vaccineFRαDCs
02
Targets
T cell receptor specific for Folate receptor alpha (FRα)
Beyond the preview
Go deeper on Multi-epitope folate receptor alpha-loaded dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Multi-epitope folate receptor alpha-loaded dendritic cell vaccine.